From the swamp by LilyGDog: Great article about short

New Post Public Reply Private Reply Replies (0) Message Board
AlanC Drano #40955
264
From the swamp by LilyGDog:

Great article about short attacks.

https://totalwealthresearch.com/2015/06/how-t...k-you-own/


How to Handle a Short Attack on a Stock You Own

Keith Fitz-Gerald Jun 03, 2015 67

An anonymous individual writing under the name “The Pump Stopper” launched a vicious attack on Ekso Bionics Holdings Inc. (OTC:EKSO) yesterday that immediately pressured the stock and caused it to drop 24.28% to close at $1.36 a share on heavy volume. Understandably, that makes a lot of people nervous.

Here’s the thing, though.

If you’ve been in this game long enough, you know what to look for and why stuff like this isn’t a big deal in the scheme of things.

Today we’re going to talk about how to recognize a legitimate short versus a short attack and what to do about it, especially when it comes to a stock you may own like Ekso.

Here’s what you need to know:

First, let’s tackle the elephant in the room – stock manipulation.

Most investors are familiar with the phrase “pump and dump.” That’s what the SEC calls a form of financial fraud used to artificially inflate the price of a stock – usually a small-cap or microcap – for personal gain by distributing misleading and false statements. That’s the pump.

The dump comes later when the fraudsters suddenly sell their stock en masse and the price drops catastrophically, causing investors to lose their money.

It used to be done in so-called boiler rooms or small back offices like those depicted in the film The Wolf of Wall Street, but now it’s most commonly perpetrated via the Internet and chat boards. Pump and dump is so extensive that these kinds of stock scams may now account for an estimated 5-15% of all spam email.

It’s blatantly illegal.

The reverse of that is called “short and distort.” That’s what’s happening with Ekso.

Instead of buying the stock in question, the perpetrators typically short the targeted company first, then release theoretically independent reports and analysis that is little more than a thinly veiled smear campaign. Once the stock has fallen, the parties involved buy to cover, bank their profits, and hopefully disappear.

This, too, is illegal, but that doesn’t change the fact that it happens all the time.

Sadly, the SEC is totally outclassed and seemingly always a step behind. They simply don’t have the resources to detect, prosecute, and punish every short and distort artist out there.

Many people wonder how this is possible, especially today. It’s not as difficult as you would think.

TV personality Jim Cramer gave a hair-raising interview in December 2006 that was aired in March 2007, describing how hedge fund managers and others push stocks higher or lower at will, stating specifically that some hedge fund managers spread false rumors to drive a stock down.

“What’s important when you are in that hedge fund mode,” he noted at the time, “is to not do anything remotely truthful because the truth is so against your view, that it’s important to create a new truth, to develop a fiction.”

Then he outlined three ways to do that:

1) Spread false rumors
2) Drive futures
3) Give information to reporters who would then spread the “news” giving it an air of legitimacy

So how do you recognize legitimate shorting versus a short “attack” or even a bluff?
There are a few giveaways:

First, real short sellers don’t hide behind anonymous Internet chat boards and cutesy names. They don’t have multiple email accounts to engage in rumor mongering. And they don’t have websites registered in Panama that have been through nine changes hosted on seven different name servers over the past eight years. That’s because guys like George Soros, Simon Cawkwell, Mark Cohodes, and Jim Chanos – some of the most famous legitimate and successful short sellers of our time don’t need to. They’re idea-driven.

Second, real short sellers don’t want attention. In fact, they want the exact opposite – not to tip anybody off so that they have an extended period of time to maximize their positions. “Short and distort” sellers typically use high volume activity to drive prices down quickly in their own self-interest rather than see them collapse under their own weight.

Third, real short sellers publish factual information if they publish anything at all. Short and distort artists string together information that may or may be germane, let alone accurate under the guise of personal opinion that makes it hard to prosecute. They rely on selected information that is taken out of context or partial truths and inference. Ethics have very little to do with how they play the game. Their sole interest is in creating short term angst that causes investors to bail so that they make money buying depressed shares.

Obviously, this is not pleasant for anybody. Short and distort artists prey on panic. They have a demoralizing effect that can hurt not only individual investors but also the companies they target by slowing down financing and growth.

Believe it or not, though, there is a silver lining.

Sometimes short sellers get burned by their own mojo. If enough people come back into a stock, that pressures the short sellers who are then forced to cover at higher prices in something called a “short burn.” The irony is that many times it’s their own actions that light the fire.

The other thing to think about is that if you buy off on the targeted company’s potential – in this case Ekso – a short attack can be a super time to pick up shares that are temporarily “on sale.”

Speaking of which…

What’s Happening with Ekso
Less than an hour after I learned about the story, I was on the phone with Ekso’s CEO Nathan Harding and CFO Max Scheder-Bieschin. As you might imagine, I share your concerns given the very serious nature of the allegations being made. So, I was keen to speak with them.

I learned that the company will be issuing a point-by-point rebuttal to The Pump Stopper and that it will be posted on Ekso’s website as soon as possible. That way all interested parties – investors and “The Pump Stopper” alike – will have access to it at the same time.

This is absolutely consistent with what you would expect from a public company in Ekso’s position and in full compliance with SEC regulations, including FD, Rule 10b5-1 and Rule 10b5-2 governing the release of material non-public information.

The Way to Defeat “Short and Distorts” Is by Keeping Perspective
I’ve studied Ekso carefully, reviewed competitive offerings carefully, visited headquarters and, talked extensively with C-level executives, Ekso users, and even health care professionals.

To be very clear, I saw and still see tremendous potential ahead.

Short attacks like this are unfortunate and gut-wrenching. But they come… and they go.

“The Pump Stopper’s” allegations seem credible at first glance, but many of them don’t make sense if you stop and think about them logically for a minute.

Take the allegation that Ekso’s testing centers now prefer competitive products, for example. These are the top treatment centers in the world. It’s not in their interest to be exclusive with any manufacturer… not Ekso, not ReWalk, not Cyberdyne. You could easily substitute their names instead of Ekso’s and instantly those companies would be on the defensive.

Instead, what these treatment centers want is to evaluate and use as many options as possible. They have a medical obligation to their clients to test any device with potential. That way they can offer the broadest spectrum of treatment.

Ekso has never communicated a goal to be the only one there, nor have they claimed that Ekso suits work on all patients. That’s an inference “The Pump Stopper” hopes you’ll make so you’ll hit the sell button and make HIM money.

Or how about the list of employee defections?

People come and go all the time, so employment ebbs and flows with every startup, not just Ekso. This isn’t unusual if you understand how Silicon Valley startups work.

Further, according to CFO Max Scheder-Bieschin, many of those same people are actually working at Ekso again at this very moment. The Pump Stopper doesn’t want you to know that because that interferes with HIS agenda.

Obviously, this situation is a long way from over, which is why I am watching it carefully. There may be more selling ahead. In fact, I’d bet on it.

But what I wouldn’t do is abandon ship in a panic.

We’re talking about a stock that’s between $1 and $2 a share. It’s not like we’re talking about Netflix at $624 a share here. So your downside is limited.

That said – to be really blunt – if you cannot handle the loss of $0.37 a share, you have no business investing in the stock market let alone a startup company like Ekso. Investing is risky and all investments can lose money. That’s why you never, ever invest money in any stock that you can’t afford to be without.

Further, if you’ve taken emotion out of the equation and properly position sized your investments, including Ekso, in keeping with the Total Wealth Tactics we’ve discussed many times, you’re not going to blow up your portfolio if something goes wrong.

And, finally, keep my original instructions in mind. Ekso is a long-term investment that will be volatile. Startups always are. That’s why my original instructions were to average down if the stock fell to $0.75 per share. Barring any change in the material information that Ekso releases shortly regarding The Pump Stopper’s allegations, those still stand.

Still, I know this is tough. Nobody likes to see a stock they believe in get clobbered for any reason… but keep it in perspective.

Microsoft is on track to do $99.3 billion in global revenue for 2015. In 1976, it booked $16,005.

Many times stocks that are ultimately big winners feel frail in the beginning.

Best regards,

Keith

https://totalwealthresearch.com/2015/06/how-t...k-you-own/

Go IPIX!!!

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ardelyx Securities Fraud Suit: Key Investor Moves

Updated Category News Views 5

Fraud Allegations: Ardelyx Under the Microscope Looks like Ardelyx has found itself neck-deep in trouble, facing a class action lawsuit over alleged securities fraud. This isn't just a storm in a teacup. We're talking about accusations of false and misleading statements tied to their commercial performance—statements that might have left investors holding the bag with...

Continue Reading
PrideStaff: 8 Years Strong on Franchise Times Top 400

Updated Category News Views 4

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Continue Reading
Steel Dynamics Gears Up for Q3 2026 Earnings Update

Updated Category News Views 6

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Continue Reading
Newfold Digital Revamps Leadership for Growth Surge

Updated Category News Views 4

Steering into New Horizons with Fresh Leadership October 2026 marks a fresh chapter for Newfold Digital, as they shuffle the deck chairs a bit and ramp up for some ambitious growth endeavors. This web and commerce tech company decided it's time to bring a few heavy hitters on board. Starting this month, watch out for Sachin Puri taking the reins as Chief Executive...

Continue Reading
CME Group Unveils First Baseball Futures Market

Updated Category News Views 6

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...

Continue Reading
Hexaware Teams with Anthropic for Game-Changing AI Move

Updated Category News Views 4

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Continue Reading
Protecting Your Family on Halloween: Safety Tips

Updated Category News Views 5

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Continue Reading
Lupin Secures FDA Nod for Key Injectable Drug

Updated Category News Views 4

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Continue Reading
Webull Faces Legal Scrutiny Over Chinese Ties

Updated Category News Views 4

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Continue Reading
Striveworks: Boosting Army's AI Edge in Indo-Pacific

Updated Category News Views 6

The world keeps marching forward, and here’s Striveworks stepping up to the plate with another big move in the military tech space. This isn't your average partnership renewal; this involves a five-year, $200 million deal to enhance battlefield AI as the U.S. Army hones its modern warfare edge in the Indo-Pacific. Now, this isn't just a battle of strategies but a battle...

Continue Reading

Top 5 Most Recently Viewed Articles

Medpace Holdings Achieves Impressive Revenue Growth Despite Challenges

Updated Category News Views 187

Medpace Holdings Reports Strong Financial Growth Medpace Holdings, Inc. (NASDAQ: MEDP), a prominent provider of clinical research services, has recently demonstrated impressive financial performance with an 8.3% revenue increase year-over-year, totaling $533.3 million in the third quarter. Net income also surged by 36.7%, reaching $96.4 million. This positive growth comes...

Continue Reading
ECARX Launches Ambitious $20M Share Buyback Initiative

Updated Category News Views 118

ECARX Unveils $20 Million Share Repurchase Plan ECARX Holdings, Inc. (Nasdaq: ECX) is taking a significant step in its financial strategy by launching a share repurchase program valued at up to $20 million. This development indicates the company's commitment to returning value to shareholders while optimizing its capital structure. Details of the Share Repurchase Program...

Continue Reading
Abpro Holdings Marks Major Milestone with Successful IPO Ceremony

Updated Category News Views 163

Abpro Holdings Celebrates Its Successful Business Combination Abpro Holdings, Inc. (Nasdaq:ABP) is excited to announce the completion of its business combination with Atlantic Coastal Acquisition Corp II. A grand bell ringing ceremony at Nasdaq marked this significant achievement, highlighting the dedication and hard work Abpro has put into this journey. Through this...

Continue Reading
Navigating Securities Losses: A Look at Compass Diversified

Updated Category News Views 169

Understanding Your Rights as an Investor Investors in Compass Diversified Holdings (NYSE: CODI) facing substantial losses have a critical opportunity to take action. Many investors find themselves in challenging positions when companies fail to disclose critical financial information. Such scenarios can lead to significant investment losses. Understanding one's rights and...

Continue Reading
Exploring Future Growth in the Blood Glucose Monitoring Market

Updated Category News Views 247

The Rising Demand for Blood Glucose Monitoring Devices As health awareness increases and diabetes continues to affect millions globally, the Blood Glucose Monitoring Device market is set to experience remarkable expansion. Valued at USD 13.49 billion in recent times, this industry is anticipated to grow significantly, reaching around USD 27.61 billion by 2032. This...

Continue Reading